Novartis India
Ticker > Company >

Novartis India share price

Novartis India Ltd.

  41.59 K   45   7 NSE: NOVARTIND BSE: 500672 SECTOR: Trading

1987.00
-15.75 (-0.79%)
BSE: 22 Sep 04:01 PM

Buy on Angel One

Price Summary

Today's High

₹ 2045.35

Today's Low

₹ 1967

52 Week High

₹ 2588

52 Week Low

₹ 750

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 4906.06 Cr.

Enterprise Value

₹ 4238.36 Cr.

No. of Shares

2.47 Cr.

P/E

50.18

P/B

5.77

Face Value

₹ 5

Div. Yield

0 %

Book Value (TTM)

₹  344.28

CASH

₹ 667.7 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

70.68 %

EPS (TTM)

₹  39.6

Sales Growth

-0.54%

ROE

11.63 %

ROCE

16.34%

Profit Growth

-7.65 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.54%
3 Year-2.2%
5 Year-1.46%

Profit Growth

1 Year-7.65%
3 Year-3.4%
5 Year34.85%

ROE%

1 Year11.63%
3 Year12.01%
5 Year9.91%

ROCE %

1 Year16.34%
3 Year16.61%
5 Year13.19%

Debt/Equity

0

Price to Cash Flow

104.99

Interest Cover Ratio

103.9048

CFO/PAT (5 Yr. Avg.)

0.839698081338577

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 70.68 0.00
Mar 2026 70.68 0.00
Dec 2025 70.68 0.00
Sep 2025 70.68 0.00
Jun 2025 70.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 103.9048.
  • The company has an efficient Cash Conversion Cycle of -14.5427 days.
  • Company has a healthy liquidity position with current ratio of 2.4474.
  • The company has a high promoter holding of 70.68%.

 Limitations

  • The company has shown a poor profit growth of -3.39712125575105% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.19621110532456% for the Past 3 years.
  • Company has contingent liabilities of 387.55 Cr.
  • The company is trading at a high EV/EBITDA of 30.5644.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 87.55 90.33 85.9 90.55 103.81
Total Expenditure 60.31 66.45 63.54 69.93 68.9
Operating Profit 27.24 23.88 22.36 20.62 34.91
Other Income 10.61 9.4 8.75 10.01 8.74
Interest 0.1 0.11 0.98 0.07 0.06
Depreciation 0.53 0.52 0.48 0.42 0.42
Exceptional Items 0 0 0 0 0
Profit Before Tax 37.22 32.65 29.65 30.14 43.17
Tax 9.6 8.43 13.56 4.89 10.96
Profit After Tax 27.62 24.22 16.09 25.25 32.21
Adjusted EPS (Rs) 11.19 9.81 6.52 10.23 13.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 399.87 378.74 335.07 356.27 354.33
Total Expenditure 373.12 313.66 269.81 264.85 260.23
Operating Profit 26.75 65.08 65.26 91.42 94.1
Other Income 33.55 58.11 61.68 41.96 38.77
Interest 4.83 1.75 1.49 0.77 1.26
Depreciation 9.65 6.06 2.61 2.19 1.95
Exceptional Items -49.64 0 0 0 0
Profit Before Tax -3.82 115.38 122.84 130.42 129.66
Tax -0.1 12.02 37.65 29.52 36.48
Net Profit -3.72 103.36 85.19 100.9 93.18
Adjusted EPS (Rs.) -1.51 41.88 34.52 40.88 37.76

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 12.34 12.34 12.34 12.34 12.34
Total Reserves 679.36 763.32 732.48 772.62 805.49
Borrowings 0 0 0 0 0
Other N/C liabilities 984 1007.77 716.25 696.83 724.89
Current liabilities 334.47 268.26 399.83 426.12 430.61
Total Liabilities 2010.17 2051.69 1860.9 1907.91 1973.33
Assets
Net Block 23.65 19.25 6.94 4.54 2.88
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1148.65 1240.75 903.63 870.18 910.78
Other N/C Assets 12 5.63 8.44 3.3 5.78
Current Assets 825.87 786.06 941.89 1029.89 1053.89
Total Assets 2010.17 2051.69 1860.9 1907.91 1973.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations -3.82 115.38 122.84 130.42 129.66
Adjustment -5.64 -48.92 -56.75 -38.8 -33.76
Changes in Assets & Liabilities 66.72 -24 9.04 -0.76 -13.91
Tax Paid -18.59 2.34 38.27 -16.29 -35.26
Operating Cash Flow 38.67 44.8 113.4 74.57 46.73
Investing Cash Flow 87.04 -153.25 33.13 -3.31 17.63
Financing Cash Flow -35.63 -30.48 -120.99 -64.15 -63.93
Net Cash Flow 90.08 -138.93 25.54 7.11 0.43

Corporate Actions

Investors Details

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY27
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY27

Company News

Novartis India Stock Price Analysis and Quick Research Report. Is Novartis India an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Novartis India. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Novartis India has a PE ratio of 49.8337024625168 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Novartis India has ROA of 4.8016% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Novartis India has a Current ratio of 2.4474.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Novartis India has a ROE of 11.6272%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Novartis India has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Novartis India has reported revenue growth of -0.5445% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Novartis India for the current financial year is 26.5571642254396%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Novartis India is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Novartis India is Rs 39.5977. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Novartis India in Ticker for free. Also, one can get the intrinsic value of Novartis India by using Valuation Calculators, which are available with a Finology ONE subscription. 

Novartis India FAQs

Q1. What is Novartis India share price today?
Ans: The current share price of Novartis India is Rs 1973.3.

Q2. What is the market capitalisation of Novartis India?
Ans: Novartis India has a market capitalisation of Rs 4872.23497201 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Novartis India?
Ans: The PE ratio of Novartis India is 49.8337024625168 and the P/B ratio of Novartis India is 5.73173515915419, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Novartis India share?
Ans: The 52-week high share price of Novartis India is Rs 2588.8, and the 52-week low share price of Novartis India is Rs 950.

Q5. Does Novartis India pay dividends?
Ans: Currently, Novartis India does not pay dividends. Dividend yield of Novartis India is around 0%.

Q6. What are the face value and book value of Novartis India shares?
Ans: The face value of Novartis India shares is Rs 5, while the book value per share of Novartis India is around Rs 344.2762. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Novartis India?
Ans: Novartis India has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Novartis India?
Ans: The ROE of Novartis India is 11.6272% and ROCE of Novartis India is 16.3365%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Novartis India a good buy for the long term?
Ans: The Novartis India long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Novartis India undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Novartis India appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Novartis India’s financials?
Ans: You can review Novartis India’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Novartis India

Novartis India Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Novartis India Ltd. is a leading pharmaceutical company in India. It is a subsidiary of the global healthcare company Novartis AG. Novartis India has been operating in the country for several decades and has established itself as a trusted provider of high-quality medicines.

Novartis India Ltd. - Share Price

Stay updated with the latest share price of Novartis India Ltd. Our website provides real-time stock prices along with historical data. Our pre-built screening tools allow you to analyze the share price performance of Novartis India over different time periods.

Novartis India Ltd. - Balance Sheet

Access the balance sheet of Novartis India Ltd. on our website. Our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools help long-term stock investors gain insights into the financial health of the company.

Novartis India Ltd. - Annual Report

Download the annual reports of Novartis India Ltd. from our website. The annual reports provide a comprehensive overview of the company's performance, financials, and strategic initiatives. They are valuable resources for investors to assess the company's long-term prospects.

Novartis India Ltd. - Dividend

Track the dividend history of Novartis India Ltd. on our website. Dividends are an important consideration for many investors looking for stable income from their investments. Novartis India regularly evaluates and announces dividends to reward its shareholders.

Novartis India Ltd. - Quarterly Results

Stay informed about the quarterly results of Novartis India Ltd. Our website provides access to the latest financial reports and insights from earnings calls. These reports help investors track the company's performance and make informed investment decisions.

Novartis India Ltd. - Stock Price

Analyze the stock price movement of Novartis India Ltd. on our website. Our pre-built screening tools and price charts allow investors to track the stock's historical performance and identify potential investment opportunities.

Novartis India Ltd. - Price Chart

Visualize the price chart of Novartis India Ltd. on our website. Price charts provide a graphical representation of the stock's price movement over time, helping investors spot trends, patterns, and potential support and resistance levels.

Novartis India Ltd. - News

Access the latest news updates about Novartis India Ltd. Our website provides a curated feed of news articles and press releases related to the company. Stay informed about the latest developments that may impact your investment decisions.

Novartis India Ltd. - Concall Transcripts

Download the concall transcripts of Novartis India Ltd. from our website. Concall transcripts are valuable resources that provide insights into the company's performance, management commentary, and future outlook as discussed during the earnings calls.

Novartis India Ltd. - Investor Presentations

Find investor presentations of Novartis India Ltd. on our website. Investor presentations offer a comprehensive overview of the company's strategy, financials, and operational highlights. These presentations are useful for investors to understand the company's business and investment potential.

Novartis India Ltd. - Promoters

Learn about the promoters of Novartis India Ltd. Promoters play a crucial role in the company's management and decision-making process. Our website provides information about the promoters and their contribution to the company's growth.

Novartis India Ltd. - Shareholders

Explore information about the shareholders of Novartis India Ltd. Shareholders play a significant role in the company's ownership and governance. Our website provides insights into the major shareholders of Novartis India and their stake in the company.

By providing comprehensive stock analysis tools, access to key financial reports, and curated news updates, our website aims to empower long-term stock investors in making informed decisions regarding Novartis India Ltd. Stay updated with the latest information and leverage our premium features for fair value calculations and in-depth analysis. 

Novartis India's Equity Structure

Novartis India has maintained a consistent share capital of Rs 12.34 Cr from March 2020 to March 2024. This reflects the company's stable equity base over the years without any dilution or increase in share capital, which can be a positive sign for investors looking at the company's equity stability.

Trend in Novartis India's Reserves

The reserves of Novartis India showed some fluctuations, decreasing from Rs 708.39 Cr in March 2020 to Rs 679.36 Cr in March 2022, before rising to Rs 763.32 Cr in March 2023 and then slightly dropping to Rs 732.48 Cr by March 2024. This indicates variations in the company’s retained earnings over the years.

Debt-Free Status of Novartis India

Remarkably, Novartis India has maintained a debt-free status from March 2020 to March 2024. This is quite significant as it reflects the company's financial prudence and strong liquidity position, making it a noteworthy point for investors analyzing the financial health of the company.

Changes in Novartis India's Liabilities and Assets

The company witnessed a significant rise in other non-current liabilities from Rs 99.38 Cr in March 2020 to a peak of Rs 1,130.65 Cr in March 2021, before settling at Rs 716.25 Cr by March 2024. Parallelly, the current assets saw a decline but recovered to Rs 941.89 Cr by March 2024, indicating dynamic asset management.

Novartis India's Loans and Advances

Loans and advances drastically increased from Rs 137.84 Cr in March 2020 to Rs 1,186.01 Cr in March 2021 and experienced variations before adjusting to Rs 903.63 Cr by March 2024. This shift reflects significant changes in the company's financial positioning and lending activities over the years.

This analysis is for the Standalone Balance Sheet of Novartis India. Analyzing these financial statements alongside broader market trends or sector performances can offer investors deeper insights into the company's standing within the pharmaceutical industry.

Read More
X